Cover Image
市場調查報告書

瘧疾:開發平台分析

Malaria - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192690
出版日期 內容資訊 英文 413 Pages
訂單完成後即時交付
價格
Back to Top
瘧疾:開發平台分析 Malaria - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 413 Pages
簡介

所謂瘧疾是寄生蟲以瘧蚊為媒介,傳染給人類所引發危及生命的疾病。得病後危及生命風險最高的是嬰幼兒、來自非傳染地區的旅客、懷孕中的女性及其體內的嬰兒等。主要症狀有發燒及惡寒、頭痛、發汗、倦怠感、脾臟肥大、噁心·嘔吐等。主要的治療方法有抗瘧疾藥和健康性的生活習慣等。

本報告提供全球各國治療瘧疾所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

瘧疾概要

治療藥的開發

  • 瘧疾開發中產品:概要
  • 瘧疾開發中產品:比較分析

各企業開發中的瘧疾治療藥

大學/研究機關研究中的瘧疾治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

瘧疾治療藥:開發中的產品一覽(各企業)

瘧疾治療藥:研究中的產品一覽(大學/研究機關別)

瘧疾治療藥的開發企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Actelion Ltd
  • Agilvax, Inc.
  • Akshaya Bio Inc.
  • Amura Holdings Limited
  • Artificial Cell Technologies, Inc.
  • AstraZeneca Plc
  • Bharat Biotech International Limited
  • Callaghan Innovation Research Ltd.
  • Carna Biosciences, Inc.
  • CEL-SCI Corporation
  • Celgene Corporation
  • Cellceutix Corporation
  • Chong Kun Dang Pharmaceutical Corp.
  • Cilian AG
  • 第一三共
  • DesignMedix, Inc.
  • Eisai
  • Genocea Biosciences, Inc.
  • GenVec, Inc.
  • Genzyme Corporation
  • GlaxoSmithKline Plc
  • Hager Biosciences, LLC
  • iBio, Inc.
  • Imaxio SA
  • Immtech Pharmaceuticals, Inc.
  • Inovio Pharmaceuticals, Inc.
  • IPCA Laboratories Limited
  • IRBM Science Park SpA
  • Jenrin Discovery, Inc.
  • Jomaa Pharma GmbH
  • Kancera AB
  • Lipocure Ltd.
  • Lipotek Pty Ltd.
  • LondonPharma Ltd
  • Merck KGaA
  • MerLion Pharmaceuticals Pte Ltd
  • Microbiotix, Inc.
  • Mucosis B.V.
  • Mymetics Corporation
  • Novartis AG
  • PaxVax, Inc.
  • Pfenex Inc.
  • Pfizer Inc.
  • Protein Potential, LLC
  • Raptor Pharmaceutical Corp.
  • Rodos BioTarget GmbH
  • Sanaria Inc.
  • Sanofi
  • SATT Lutech SAS
  • SBI Pharmaceuticals Co., Ltd.
  • SEEK Group
  • Selecta Biosciences, Inc.
  • Sigma-Tau S.p.A.
  • 武田藥品工業
  • Telormedix SA
  • Tomegavax, Inc.
  • VLP Biotech, Inc.
  • Zydus Cadila Healthcare Limited

瘧疾:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

瘧疾治療藥:開發中產品的最新趨勢

瘧疾治療藥:開發暫停的產品

瘧疾治療藥:開發中止的產品

瘧疾相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8670IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Pipeline Review, H2 2016, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malaria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malaria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Malaria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 7, 62 and 29 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14, 46 and 41 molecules, respectively.Malaria.

Malaria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malaria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Malaria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malaria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malaria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malaria (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malaria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malaria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Malaria Overview
  • Therapeutics Development
  • Malaria - Therapeutics under Development by Companies
  • Malaria - Therapeutics under Investigation by Universities/Institutes
  • Malaria - Pipeline Products Glance
  • Malaria - Products under Development by Companies
  • Malaria - Products under Investigation by Universities/Institutes
  • Malaria - Companies Involved in Therapeutics Development
  • Malaria - Therapeutics Assessment
  • Drug Profiles
  • Malaria - Dormant Projects
  • Malaria - Discontinued Products
  • Malaria - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Malaria, H2 2016
  • Number of Products under Development for Malaria - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
  • Malaria - Pipeline by 4SC AG, H2 2016
  • Malaria - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Malaria - Pipeline by Actelion Ltd, H2 2016
  • Malaria - Pipeline by Agilvax Inc, H2 2016
  • Malaria - Pipeline by Akshaya Bio Inc., H2 2016
  • Malaria - Pipeline by Allergy Therapeutics Plc, H2 2016
  • Malaria - Pipeline by Amura Holdings Limited, H2 2016
  • Malaria - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
  • Malaria - Pipeline by Artificial Cell Technologies, Inc., H2 2016
  • Malaria - Pipeline by AstraZeneca Plc, H2 2016
  • Malaria - Pipeline by Bharat Biotech International Limited, H2 2016
  • Malaria - Pipeline by Callaghan Innovation Research Ltd., H2 2016
  • Malaria - Pipeline by Carna Biosciences, Inc., H2 2016
  • Malaria - Pipeline by CEL-SCI Corporation, H2 2016
  • Malaria - Pipeline by Celgene Corporation, H2 2016
  • Malaria - Pipeline by Cellceutix Corporation, H2 2016
  • Malaria - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Malaria - Pipeline by Cilian AG, H2 2016
  • Malaria - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Malaria - Pipeline by DesignMedix, Inc., H2 2016
  • Malaria - Pipeline by Eisai Co., Ltd., H2 2016
  • Malaria - Pipeline by GenVec, Inc., H2 2016
  • Malaria - Pipeline by Genzyme Corporation, H2 2016
  • Malaria - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Malaria - Pipeline by Hager Biosciences, LLC, H2 2016
  • Malaria - Pipeline by Horizon Pharma Plc, H2 2016
  • Malaria - Pipeline by iBio, Inc., H2 2016
  • Malaria - Pipeline by Imaxio SA, H2 2016
  • Malaria - Pipeline by Immtech Pharmaceuticals, Inc., H2 2016
  • Malaria - Pipeline by Immunovaccine Inc, H2 2016
  • Malaria - Pipeline by IPCA Laboratories Limited, H2 2016
  • Malaria - Pipeline by IRBM Science Park SpA, H2 2016
  • Malaria - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Malaria - Pipeline by Jomaa Pharma GmbH, H2 2016
  • Malaria - Pipeline by Kancera AB, H2 2016
  • Malaria - Pipeline by Kymab Limited, H2 2016
  • Malaria - Pipeline by Lipocure Ltd., H2 2016
  • Malaria - Pipeline by Lipotek Pty Ltd., H2 2016
  • Malaria - Pipeline by LondonPharma Ltd, H2 2016
  • Malaria - Pipeline by Merck & Co., Inc., H2 2016
  • Malaria - Pipeline by Merck KGaA, H2 2016
  • Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2016
  • Malaria - Pipeline by Microbiotix, Inc., H2 2016
  • Malaria - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Malaria - Pipeline by Mucosis B.V., H2 2016
  • Malaria - Pipeline by Mymetics Corporation, H2 2016
  • Malaria - Pipeline by Novartis AG, H2 2016
  • Malaria - Pipeline by PaxVax, Inc., H2 2016
  • Malaria - Pipeline by Pfenex Inc., H2 2016
  • Malaria - Pipeline by Pfizer Inc., H2 2016
  • Malaria - Pipeline by Protein Potential, LLC, H2 2016
  • Malaria - Pipeline by Rodos BioTarget GmbH, H2 2016
  • Malaria - Pipeline by Sanaria Inc., H2 2016
  • Malaria - Pipeline by Sanofi, H2 2016
  • Malaria - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016
  • Malaria - Pipeline by Selecta Biosciences, Inc., H2 2016
  • Malaria - Pipeline by Sigma-Tau S.p.A., H2 2016
  • Malaria - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Malaria - Pipeline by Telormedix SA, H2 2016
  • Malaria - Pipeline by Tomegavax, Inc., H2 2016
  • Malaria - Pipeline by VLP Biotech, Inc., H2 2016
  • Malaria - Pipeline by VLP Therapeutics, LLC, H2 2016
  • Malaria - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Malaria - Dormant Projects, H2 2016
  • Malaria - Dormant Projects (Contd..1), H2 2016
  • Malaria - Dormant Projects (Contd..2), H2 2016
  • Malaria - Dormant Projects (Contd..3), H2 2016
  • Malaria - Dormant Projects (Contd..4), H2 2016
  • Malaria - Dormant Projects (Contd..5), H2 2016
  • Malaria - Dormant Projects (Contd..6), H2 2016
  • Malaria - Dormant Projects (Contd..7), H2 2016
  • Malaria - Dormant Projects (Contd..8), H2 2016
  • Malaria - Dormant Projects (Contd..9), H2 2016
  • Malaria - Dormant Projects (Contd..10), H2 2016
  • Malaria - Dormant Projects (Contd..11), H2 2016
  • Malaria - Dormant Projects (Contd..12), H2 2016
  • Malaria - Discontinued Products, H2 2016
  • Malaria - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Malaria, H2 2016
  • Number of Products under Development for Malaria - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top